Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for September 23, 2026, at 9 a.m. EDT. This appearance matters because it places Helus Pharma at the center of a high-profile industry forum focused on innovative psychiatric treatments, signaling the company's growing prominence in the mental health space and offering investors a direct update on its strategic direction.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder, and Helus Pharma maintains an extensive research portfolio of investigational NSAs. Operating in Canada, the United States, the United Kingdom, and Ireland, the company is positioning itself as a leader in the emerging field of serotonergic therapeutics.
The TD Cowen summit brings together experts and companies at the forefront of neuropsychiatry, and Halstead's participation provides a platform to discuss Helus Pharma's class-leading data and its potential to improve the treatment landscape. For investors, this event could serve as a catalyst for increased visibility and credibility, especially as the company advances its late-stage programs. The live webcast will allow stakeholders to hear firsthand about the company's progress and vision. Those interested in learning more about Helus Pharma can visit www.helus.com for company updates. The full press release is available at https://nnw.fm/8dLEZ.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, disseminated this announcement. As one of 75+ brands within the Dynamic Brand Portfolio at IBN, NetworkNewsWire provides access to a vast network of wire solutions via InvestorWire, including editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution. The platform also offers a full array of tailored corporate communications solutions. For complete terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
